PT2061452E - Utilização anticancerosa de ácido cafeico e derivados - Google Patents

Utilização anticancerosa de ácido cafeico e derivados Download PDF

Info

Publication number
PT2061452E
PT2061452E PT07826053T PT07826053T PT2061452E PT 2061452 E PT2061452 E PT 2061452E PT 07826053 T PT07826053 T PT 07826053T PT 07826053 T PT07826053 T PT 07826053T PT 2061452 E PT2061452 E PT 2061452E
Authority
PT
Portugal
Prior art keywords
abl
dihydroxyphenyl
bcr
compound
treatment
Prior art date
Application number
PT07826053T
Other languages
English (en)
Portuguese (pt)
Inventor
Meenakshi Sivakumar
Kalpana Sanjay Joshi
Valmik Sopan Aware
Vilas Sampatrao Wagh
Amit Deshpande
Ankush Gangaram Sarde
Somesh Sharma
Original Assignee
Piramal Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Life Sciences Ltd filed Critical Piramal Life Sciences Ltd
Publication of PT2061452E publication Critical patent/PT2061452E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT07826053T 2006-09-01 2007-08-20 Utilização anticancerosa de ácido cafeico e derivados PT2061452E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84206006P 2006-09-01 2006-09-01

Publications (1)

Publication Number Publication Date
PT2061452E true PT2061452E (pt) 2012-01-13

Family

ID=39015871

Family Applications (1)

Application Number Title Priority Date Filing Date
PT07826053T PT2061452E (pt) 2006-09-01 2007-08-20 Utilização anticancerosa de ácido cafeico e derivados

Country Status (12)

Country Link
US (1) US20100010002A1 (enExample)
EP (1) EP2061452B1 (enExample)
JP (1) JP2010502586A (enExample)
AT (1) ATE530176T1 (enExample)
AU (1) AU2007290960B2 (enExample)
CA (1) CA2662126A1 (enExample)
DK (1) DK2061452T3 (enExample)
ES (1) ES2376277T3 (enExample)
IL (1) IL197262A0 (enExample)
PT (1) PT2061452E (enExample)
TW (1) TW200812955A (enExample)
WO (1) WO2008026125A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722665B2 (en) 2008-11-07 2014-05-13 Council Of Scientific & Industrial Research Cinnamido-pyrrolo[2,1-C][1,4]benzodiazepines as potential anticancer agents and process for the preparation thereof
CN101456890B (zh) * 2008-12-17 2011-02-02 中南大学 白血病bcr/abl融合基因mRNA的特异性抑制剂
EP2427416B1 (en) 2009-05-04 2016-03-09 Prometic Pharma Smt Limited Substituted aromatic compounds and pharmaceutical uses thereof
BR112012021476A2 (pt) 2010-02-25 2019-09-24 Piramal Entpr Ltd composto, processo para preparação do composto, composição farmacêutica compreendendo uma quantidade terapeuticamente eficaz do composto e emprego de tal composto
CN105997967B (zh) 2010-10-27 2019-08-23 普罗米蒂克医药Smt有限公司 用于治疗癌症的化合物和组合物
US20140127316A1 (en) * 2011-05-20 2014-05-08 New York University Propolis and caffeic acid phenethyl ester and uses thereof
US20160194718A1 (en) * 2013-05-21 2016-07-07 Dana-Farber Cancer Institute, Inc. Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Cancer Using Histone H3K27ME3 Biomarkers and Modulators
WO2017161093A1 (en) * 2016-03-17 2017-09-21 Musc Foundation For Research Development Caffeic acid derivatives and uses thereof
BR112022004890A2 (pt) * 2019-09-17 2022-06-07 Enzene Biosciences Ltd Composições para uso na inibição de src quinase e no tratamento e na prevenção de distúrbios associados
EP4023301A3 (en) * 2020-12-29 2022-09-07 Huscion Co., Ltd. Piperlongumine-based compound and immuno regulator comprising the same
US20240109855A1 (en) * 2021-01-14 2024-04-04 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Anti-quorum sensing, anti-biofilm, and inflammation attenuating compounds, compositions, and methods of using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216024A (en) * 1987-07-28 1993-06-01 Baylor College Of Medicine Cell growth inhibitors and methods of treating cancer and cell proliferative diseases
US5008441A (en) * 1987-08-04 1991-04-16 The Trustees Of Columbia University In The City Of New York Caffeic acid esters and methods of producing and using same
DE60206531T2 (de) * 2002-05-31 2006-07-13 Council Of Scientific & Industrial Research Ein kräutermolekül als potentielles anti-leukämisches arzneimittel
WO2004004708A1 (en) * 2002-07-08 2004-01-15 Council Of Scientific And Industrial Research A pharmaceutical composition useful for treating chronic myeloid leukemia
US20040006138A1 (en) * 2002-07-08 2004-01-08 Council Of Scientific Pharmaceutical composition useful for treating chronic myeloid leukemia
US20050282892A1 (en) * 2002-07-08 2005-12-22 Santu Bandyopadhyay Pharmaceutical composition useful for treating chronic myeloid leukemia
US20070161704A1 (en) * 2002-07-08 2007-07-12 Council Of Scientific And Industrial Research Pharmaceutical composition useful for treating chronic myeloid leukemia
WO2005099721A2 (en) * 2004-04-15 2005-10-27 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
US20060045887A1 (en) 2004-08-25 2006-03-02 Gavish-Galilee Bio Applications Ltd. Mushroom extracts having anticancer activity

Also Published As

Publication number Publication date
ES2376277T3 (es) 2012-03-12
IL197262A0 (en) 2009-12-24
TW200812955A (en) 2008-03-16
EP2061452A2 (en) 2009-05-27
DK2061452T3 (da) 2012-02-13
AU2007290960A1 (en) 2008-03-06
EP2061452B1 (en) 2011-10-26
JP2010502586A (ja) 2010-01-28
WO2008026125A3 (en) 2008-10-02
ATE530176T1 (de) 2011-11-15
AU2007290960B2 (en) 2013-04-18
US20100010002A1 (en) 2010-01-14
CA2662126A1 (en) 2008-03-06
WO2008026125A2 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
AU2007290960B2 (en) Anticancer use of caffeic acid and its derivatives
JP2010502586A5 (enExample)
WO2021178846A1 (en) Methods of treating estrogen receptor-associated diseases
US20220274972A1 (en) Class of triaromatic compounds targeting bifunctional phosphorylation site of stat3 and applications thereof
ES2554330T3 (es) Derivados de quinazolina y uso terapéutico de los mismos
HUP0500422A2 (hu) Eljárás az akut mieloid leukémia indolin-származékokkal való kezelésére
WO2013116786A1 (en) Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer
EP2433636A1 (en) Treatment of Malignant Diseases
US20200239487A1 (en) 1,5-disubstituted 1,2,3-triazoles are inhibitors of rac/cdc42 gtpases
US11465978B2 (en) Anthranilic amides and the use thereof
KR20210027382A (ko) 접히지 않은 단백질 반응의 활성화제
JP5289310B2 (ja) 微小管破壊剤及びそれを含有する癌細胞増殖抑制剤
WO2018068665A1 (zh) 微管蛋白抑制剂
JP2013515766A (ja) イマチニブジクロロ酢酸塩及びそれを含む抗癌剤組成物
US20090197906A1 (en) Reversion of malignant phenotype with 9-hydroxy ellipticine derivatives
JP6239103B2 (ja) チロシンキナーゼ阻害活性を有する物質ならびにその調製方法および使用
CN109467554B (zh) 吲哚-芳杂环哌嗪(啶)类衍生物及其在抗抑郁症中的应用
EP3654959A2 (en) Compositions and methods for treatment of central nervous system tumors
JP5313971B2 (ja) ５−置換４，７−ジメトキシ−１，３−ベンゾジオキソール（５−Ｓｕｂｓｔｉｔｕｔｅｄ４，７−ｄｉｍｅｔｈｏｘｙ−１，３−ｂｅｎｚｏｄｉｏｘｏｌｅｓ）の結腸直腸癌（ｃｏｌｏｒｅｃｔａｌｃａｎｃｅｒ）治療用医薬品
CN112996521A (zh) 用于诊断、治疗和预防赘生性和神经性障碍的组合物和方法
US9296730B2 (en) Aurora kinase inhibitors
CN112513000A (zh) 新型联苯衍生物化合物及其用途
US20040266843A1 (en) Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
JP2019014685A (ja) 抗がん剤
WO2022020605A1 (en) Treatment of metastasized estrogen receptor positive breast cancer